# A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).

> **NCT00796757** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 146 (actual)

## Conditions studied

- Renal Cell Cancer

## Interventions

- **DRUG:** bevacizumab [Avastin]
- **DRUG:** interferon alfa-2a

## Key facts

- **NCT ID:** NCT00796757
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2015-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00796757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00796757, "A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00796757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*